4//SEC Filing
Sander Dale A. 4
Accession 0001104659-21-110523
CIK 0001818382other
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 4:09 PM ET
Size
15.5 KB
Accession
0001104659-21-110523
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Sander Dale A.
CFO and Chief Corp. Deve. Off.
Transactions
- Award
Stock Options (right to buy)
2021-08-26+39,389→ 39,389 totalExercise: $2.56Exp: 2025-09-01→ Common Stock (39,389 underlying) - Award
Stock Options (right to buy)
2021-08-26+17,068→ 17,068 totalExercise: $6.54Exp: 2028-04-12→ Common Stock (17,068 underlying) - Award
Stock Options (right to buy)
2021-08-26+1,575→ 1,575 totalExercise: $10.28From: 2021-12-14Exp: 2030-12-14→ Common Stock (1,575 underlying) - Award
Stock Options (right to buy)
2021-08-26+210,077→ 210,077 totalExercise: $10.28From: 2022-05-14Exp: 2031-05-16→ Common Stock (210,077 underlying) - Award
Stock Options (right to buy)
2021-08-26+183,817→ 183,817 totalExercise: $10.28From: 2021-11-09Exp: 2031-01-14→ Common Stock (183,817 underlying)
Footnotes (5)
- [F1]Options are fully vested and exercisable.
- [F2]On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
- [F3]Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.
- [F4]Options vest annually in three equal installments on 11/09/2021, 11/09/2022, and 11/09/2023.
- [F5]Options vest annually in three equal installments on 05/14/2022, 05/14/2023, and 05/14/2024.
Documents
Issuer
Humacyte, Inc.
CIK 0001818382
Entity typeother
Related Parties
1- filerCIK 0001878193
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 4:09 PM ET
- Size
- 15.5 KB